Malin Corporation (MLC.IR) Stock Price
Malin Corporation Price
Over the last 5 years Malin Corporation grew revenue by 12.4% annually, reaching 41.00 M EUR. Earnings per share have declined at 38.2% per year over the last 2 years. For Malin Corporation, the net margin of 213.9% is up versus -198.3% a few years ago. The consensus 12-month price target for Malin Corporation is 15.81 EUR, about 165.7% above where the stock trades today. Of 5 analysts, 4 rate the stock a buy — an overall Buy consensus.
Malin Corporation stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Malin Corporation business model & stock analysis
Frequently asked questions about Malin Corporation
The business model of Malin Corporation PLC is focused on strategic investments in life sciences companies with significant growth potential. Malin aims to provide capital, expertise, and operational support to enable these companies to reach their full potential and generate substantial returns. By investing in a diverse portfolio of innovative life sciences businesses, Malin seeks to create value for its shareholders and contribute to the advancement of breakthrough technologies and therapies. With an emphasis on long-term partnerships, Malin aims to drive sustainable growth in the life sciences sector by identifying and supporting promising companies in areas such as biotechnology, pharmaceuticals, and medical devices.
Malin Corporation PLC is primarily active in the industries of healthcare and life sciences.
The main competitors of Malin Corporation PLC in the market are [competitor names]. These competitors pose a challenge to Malin Corporation PLC by offering similar products and services [specific to the industry], thereby competing for market share. However, Malin Corporation PLC has positioned itself uniquely in the market by [highlighting key differentiators or strengths], giving it a competitive edge. Despite the competition, Malin Corporation PLC continues to strive for excellence through its innovative offerings and strategic initiatives in order to maintain and expand its market presence.
Malin Corporation PLC is an Irish-based global life sciences investment company. Founded in 2015, its primary focus is on creating long-term shareholder value through strategic investments in innovative companies. Malin seeks to partner with businesses across various life sciences sectors, including biotechnology, therapeutics, medical devices, and diagnostics. With a goal to support the development of breakthrough technologies, Malin engages in active collaboration and provides financial and strategic support to its investee companies. While continually expanding its portfolio, Malin maintains a strong commitment to driving advances in healthcare and delivering value to its shareholders.
Malin Corporation PLC has achieved several significant milestones. Firstly, the company successfully completed its initial public offering (IPO) on the Irish Stock Exchange in 2015, raising substantial funds for its investment portfolio. In 2016, Malin Corporation acquired a strategic stake in Poseida Therapeutics, an innovative gene engineering company. The company further expanded its portfolio by investing in promising life science companies like Immunocore, Kymab, and Serenus Biotherapeutics. In 2019, Malin Corporation celebrated the FDA approval of its investee company, Outpost Medicine's drug, for the treatment of overactive bladder. These achievements demonstrate Malin Corporation PLC's commitment to investing in breakthrough medical technologies and its potential for long-term growth.
Malin Corporation PLC primarily operates in Ireland.
Malin Corporation PLC represents a strong set of values and a well-defined corporate philosophy. The company is dedicated to delivering long-term shareholder value through strategic investments in innovative life sciences companies. Malin Corporation aims to support diverse and forward-thinking businesses that have the potential to positively impact global health. By fostering growth and nurturing breakthrough technologies, Malin Corporation PLC promotes collaboration and excellence within the life sciences industry. With a steadfast commitment to ethical practices and responsible investments, Malin Corporation PLC strives to enhance patient outcomes and contribute to the advancement of healthcare worldwide.
Analysts currently set an average price target of 15.81 EUR for the Malin Corporation stock (median: 15.81 EUR), implying +165.7 % versus the latest price. The consensus is based on 5 analyst ratings.
5 analysts currently rate the Malin Corporation stock: 4 recommend buying, 1 holding and 0 selling.
Malin Corporation PLC is an innovative Irish company specializing in investing in medical products. The company operates in various business areas, including the development and manufacture of pharmaceutical products, investment in innovative biotechnology startups, and the establishment of partnerships for scientific research projects. The manufacture of medical products is Malin's main business area. The company offers a wide range of products, ranging from drugs for rare diseases to antibiotics. The products are manufactured to the highest quality standards and are available to patients worldwide. An important part of Malin's business model is investing in innovative biotechnology startups. The company strives to find and support new technologies that contribute to improving human health. By collaborating with other companies and investors in the biotechnology field, Malin can advance innovative research and development that is of great benefit to its customers. Malin has also established partnerships for scientific research projects. Together with internationally leading research institutions and universities, the company is committed to the development of new drugs and therapies to meet the needs of patients. This collaboration aims to achieve scientific breakthroughs and find new treatment options for serious diseases. Overall, Malin's business model is focused on developing and providing innovative and effective drugs and therapies for patients. The company places special emphasis on adhering to high standards in research and production. By collaborating with other companies and research institutions, Malin achieves a broader base of knowledge, technology, and skills to remain competitive in the market. In summary, Malin Corporation PLC is an innovative company with a wide portfolio of medical products, investments in biotechnology startups, and research collaborations. With its focus on quality and innovation, Malin is a growing company that contributes to improving human health with its business model.
The revenue cannot currently be calculated for Malin Corporation.
The expected profit of Malin Corporation is -4.19 M EUR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Malin Corporation is currently -26.91. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Malin Corporation stock.
The P/S cannot be calculated for Malin Corporation currently.
The Eulerpool Quality Score for Malin Corporation is 2/10.
The ISIN of Malin Corporation is IE00BVGC3741. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Malin Corporation is MLC.IR. The ticker symbol is used to trade Malin Corporation shares on the stock exchange.
Malin Corporation stock
Malin Corporation Peer Group
Malin Corporation FIGI
All fundamentals and in-depth analysis of Malin Corporation
Our stock analysis for Malin Corporation stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Malin Corporation. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.